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Abstract
Purpose: Stereotactic body radiation therapy (SBRT) has demonstrated clinical benefits for patients with metastatic and/or unresectable
cancer. Technical considerations of treatment delivery and nearby organs at risk can limit the use of SBRT in large tumors or those in
unfavorable locations. Spatially fractionated radiation therapy (SFRT) may address this limitation because this technique can deliver high-
dose radiation to discrete subvolume vertices inside a tumor target while restricting the remainder of the target to a safer lower dose.
Indeed, SFRT, such as GRID, has been used to treat large tumors with reported dramatic tumor response and minimal side effects. Lattice
is a modern approach to SFRT delivered with arc-based therapy, which may allow for safe, high-quality SBRT for large and/or deep
tumors.
Methods and Materials: Herein, we report the results of a dosimetry and quality assurance feasibility study of Lattice SBRT in 11
patients with 12 tumor targets, each 10 cm in an axial dimension. Prior computed tomography simulation scans were used to generate
volumetric modulated arc therapy Lattice SBRT plans that were then delivered on clinically available Linacs. Quality assurance testing
included external portal imaging device and ion chamber analyses.
Results: All generated plans met the standard SBRT dose constraints, such as those from the American Association of Physicists in
Medicine Task Group 101. Additionally, we provide a step-by-step approach to generate and deliver Lattice SBRT plans using
commercially available treatment technology.
Conclusions: Lattice SBRT is currently being tested in a prospective trial for patients with metastatic cancer who need palliation of large
tumors (NCT04553471, NCT04133415).
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Metastatic or unresectable cancer is responsible for
significant morbidity and mortality in patients with solid
tumors.1 Stereotactic body radiation therapy (SBRT) is
emerging as a high-value treatment option for these
patients, offering improved symptom palliation across
cancer types and extended survival in oligometastatic
populations. Unfortunately, SBRT can be difficult to
deliver safely for large tumors. Large tumors may be near
surrounding organs at risk (OARs), which can make
planning difficult.2,3 Prior studies have shown that SBRT
may be associated with unacceptable toxicity for tumors
>5 cm.4,5
Spatially fractionated radiation therapy (SFRT) is a
radiation therapy technique that theoretically allows for
safe dose escalation for large tumors. Specialized beam
collimation creates high-dose peaks organized throughout
a target volume with intervening low-dose valleys.6 SFRT
planned with a 2-dimensional technique, such as GRID
radiation therapy, has been evaluated for large soft-tissue
sarcomas, and is associated with excellent local control
and low toxicity in prior case series.7,8 The GRID tech-
nique attempts to achieve a differential high-dose peak
surrounded by lower-dose valleys, using either a precast
block or multileaf collimators (MLCs).9 Although GRID
is more widely accessible, newer SFRT techniques (eg,
Lattice) offer improved dose distribution and OAR
sparing compared with GRID. Lattice creates small, high-
dose islands within a sea of lower doses covering the
entire tumor volume. Compared with GRID, Lattice may
be more beneficial for large or deep-seated tumors sur-
rounded by OARs.10
To safely deliver SBRT to large and/or deep-seated
tumors, we created a Lattice SBRT technique that delivers
2000 cGy in 5 fractions to the entire tumor target with a
simultaneous integrated boost of 6670 cGy to vertices
arranged geometrically inside the tumor. Herein, we
describe the Lattice SBRT planning process, resulting
dosimetric parameters of 12 pilot Lattice SBRT plans, and
their quality assurance (QA) results.
Methods and Materials
This study was approved by our institutional review
board. We retrospectively identified 12 large tumors >10
cm in 11 patients previously treated at our institution.
Patient and tumor characteristics were extracted from the
electronic medical record. A step-by-step guide to the
Lattice SBRT contouring and treatment planning process
is available in Supplementary Material E1. The Lattice
SBRT prescription was created on the assumption that the
tumor planning target volume (PTV) should receive at
least a standard 5-fraction palliative dose of 2000 cGy.
Spatially fractionated techniques have traditionally
created a peakevalley dose gradient of approximately
100% to 30%6; therefore, a simultaneous integrated boost
of 6670 cGy was selected as a Lattice boost dose
prescription.
To generate the desired high-gradient dose distribu-
tion, our Lattice SBRT technique uses a geometric
arrangement of spherical vertices, each with a diameter of
1.5 cm, 6-cm center-to-center spacing, and separation of
3.0 cm between each successive axial plane of spheres.
A representative schematic is shown in Figure 1. The
selection of these Lattice SBRT planning technique
Figure 1 (A) Geometric representation of sphere placement. Yellow dots represent the 1.5 cm diameter planning target volume (PTV)
_6670 target vertices, and dotted line vertices represent the transposed target vertices from adjacent planes. Axial planes where vertices
are placed are separated by 3 cm in plane. Within a plan, vertices are separated by 6 cm center to center (4.5 cm edge to edge) in
orthogonal axes, and 3O2 cm along the diagonal. (B) Axial computed tomography slices of a target with the yellow outlined target
vertices (PTV_6670) in each plane, red gross tumor volume_2000, and green PTV_2000. Magenta arrows denote cropped vertices in
PTV_6670 that extend outside of the gross tumor volume_2000. (C) Dose distribution after volumetric modulated arc therapy planning
for the target with blue representing 20 Gy and red 66.7 Gy. (A color version of this figure is available at https://doi.org/10.1016/j.adro.2
020.100639.)
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dimensions was based on previously published ap-
proaches, which used boost target vertices of 1 to 2 cm in
diameter, spaced 2 to 3 cm apart throughout the gross
tumor volume (GTV).11,12 These vertices are defined
within a physician-contoured GTV (GTV_2000), which
included all visually identifiable gross disease. The
GTV_2000 was expanded by 0.5 to 1.0 cm to create the
PTV_2000, which was to receive 2000 cGy in 5 fractions.
To generate the geometric lattice, the axial plane with the
largest cross dimension within the GTV_2000 was first
selected. Then, a 3  3  3 cm grid guide was overlaid on
the GTV_2000, and the high-dose target vertices were
placed at the grid intersections using a 1.5 cm diameter
3-dimensional brush to create the PTV_6670. The
PTV_6670 high-dose target vertices were alternated with
1.5 cm diameter avoidance vertices (ie, PTV_Avoid) such
that the center of a PTV_6670 vertex was 3 cm apart from
a PTV_Avoid vertex. This process was repeated every 3
cm in the superioreinferior direction with vertices offset
by 3.0 cm with respect to axial slices above and below.
All PTV_6670 vertices extending outside of a 5 mm
contraction of the GTV_2000 were completely removed
to minimize spill of the 30 Gy isodose volume outside the
PTV_2000. Additionally, any PTV_6670 vertices located
within 1.5 cm of an OAR were completely removed to
limit the dose to normal tissue given any uncertainties at
the time of treatment. Finally, a PTV_Control structure
was made by expanding PTV_6670 by 8 mm and sub-
tracting this from PTV_2000, and was used to assess dose
falloff between adjacent PTV_6670 vertices.
The Lattice plan generation attempted to achieve a goal
of 95% prescription dose coverage to at least 95% of
both the PTV_2000 and PTV_6670. To achieve the high-
dose gradients, each of the interspaced PTV_Avoid
vertices required a minimum dose between 19 and 20 Gy.
High maximum point doses were allowed within the
PTV_6670 vertices, with a maximum dose limited to 80
Gy. OAR constraints consistent with 5-fraction SBRT
published in American Association of Physicists in
Medicine (AAPM) Task Group 101 were used in plan-
ning directives.13
Volumetric modulated arc therapy (VMAT) was used
to achieve the internal high-dose gradients, target cover-
ages, and OAR objectives. VMAT plans are hypothesized
to offer superior target coverage, reduce high-dose spill,
and better spare OARs compared with 3-dimensional
conformal radiation therapy (CRT) for Lattice radiation
therapy.14,15 After an initial attempt to generate both
3-dimensional CRT and VMAT comparison plans for
Lattice SBRT, we did not further pursue 3-dimensional
CRT plans because, regardless of the number of beam
angles, we would not achieve OAR dose constraints while
attaining our desired dose gradient. All plans were
delivered on a Varian Truebeam using standard Millen-
nium 120 MLC (5 mm/10 mm MLC widths). Once the
Lattice SBRT contouring and treatment planning process
was finalized, planning was completed for all 12 tumors
using a Varian Eclipse treatment planning system, version
15.6 (Varian Medical Systems, Palo Alto, CA) using
patient computed tomography simulation scans.
After treatment planning, physician and physicist re-
view, and plan approval, plan integrity and deliverability
was evaluated per the standard clinical SBRT QA pro-
tocol. This included 2-dimensional external portal imag-
ing device (EPID) portal dosimetry to measure fluence
throughout each angle of the beam’s arc, 1-dimensional
ion chamber (IC) absolute dose measurements within the
PTV_6670 and PTV_Avoid (low-dose) vertices, and
machine parameter delivery verification using an in-house
log-file program called Dyna QA.16 For EPID portal
dosimetry, 2-dimensional fluence maps were measured
for each arc, and evaluated against the calculated fluence
Table 1 Patient tumor characteristics for Lattice stereotactic body radiation therapy dosimetric and quality assurance analyses,
ranked from smallest to largest volume
Target Histology Site Gross tumor volume, cm3 Largest axial dimension, cm
1 Cervical squamous cell carcinoma Central pelvis 350 10
2 Leiomyosarcoma Right abdomen 430 10.5
3 Cholangiocarcinoma Right abdomen 450 10
4 Melanoma Mediastinum 490 13
5* Undifferentiated sarcoma Left lung 450 12.5
6* Undifferentiated sarcoma Right neck 615 12
7 Leiomyosarcoma Left lung 745 12.5
8 Liposarcoma Central pelvis 1805 13
9 Sarcomatoid carcinoma Right abdomen 940 13.5
10 Liposarcoma Right pelvis 1035 14.5
11 Melanoma Left abdomen/pelvis 1600 15.5
12 Malignant peripheral nerve sheath tumor Left abdomen/pelvis 4475 18.5
* Targets 5 and 6 are separate tumor targets from the same patient.
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using 3%/3 mm (95% pass rate) and 2%/2 mm (90% pass
rate) criteria across all pixels. The 2-dimensional planar
measurements provided evidence of the accuracy of the
high-dose gradients within the GTV_2000. The 1-
dimensional IC measurements were completed using a
small-field Exradin A16 IC (Standard Imaging, Mid-
dleton, WI) placed in an in-house designed solid water
phantom at locations corresponding to the PTV_6670 and
PTV_Avoid vertices, with 1 measurement in each struc-
ture captured per patient. A Dyna QA report was gener-
ated from the treatment machine log files and analyzed
with in-house software (eg, MLC movement, gantry
rotation, monitor units delivered).16
Results
The 11 patients had tumors of various histologies that
were located in a range of anatomic locations (Table 1).
Tumors had a median volume of 687.5 cc (range,
350e4440 cc) and a median greatest axial dimension of
12.75 cm (range, 10e18.5 cm). VMAT plans were
created using flattening filter-free beams, and multiple full
or partial noncoplanar arcs with couch kicks up to 15
based on available clearance of the treatment couch. Plans
used 6MV or 10MV energies with 10MV plans overall
resulting in less monitor units. A collimator rotation of
15 to 90 and jaw tracking were used for all plans.
Treatment delivery times were acquired during the IC QA
process, and ranged from 9 to 16 minutes (mean: 12.3
minutes), inclusive of couch kicks but exclusive of patient
setup, imaging, or alignment.
All plans, except 1, met the dose constraints for OARs
(Table E1). The skin dose constraint could not be ach-
ieved in this patient who had a very large sarcoma
metastasis to the neck where the tumor extended close to
the skin. All targets achieved >95% coverage for the
PTV_2000 and PTV_6670 (Table 2). Target 12, the
largest target, achieved adequate dose coverage and OAR
sparing; however, the Dmean of the PTV_Avoid was the
highest of this series, indicating that achieving desired
dose falloff in exceptionally large targets may be difficult.
An additional metric, termed the Lattice composite, was
defined as PTV_6670 divided by GTV_2000 to represent
the volume of tumor target filled by high-dose vertices.
All patients had a Lattice composite of approximately 2%
to 4%.
All 2-dimensional EPID, IC, and Dyna QA results
achieved the thresholds specified (Table E2). The IC
measurements, taken within the PTV_6670 structures,
were within 3% of the expected dose predicted by the
treatment planning system. A larger deviation of agree-
ment was observed for the low-dose IC measurements
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Discussion
This study demonstrates that the proposed Lattice
SBRT technique adheres to established SBRT safety
guidelines, and can be planned and delivered on standard
commercially available equipment. Lattice SBRT plans
were successfully created for tumors ranging from 350 to
4440 cc, and the plans met tumor coverage objectives and
OAR dose constraints for 5-fraction SBRT. The planning
procedure was critical to consistently achieve the high-
dose gradients characteristic of Lattice planning. The 1.5
cm diameter of PTV_6670 and PTV_Avoid vertices was
selected for 3 reasons. First, the diameter represented a
volume that approached the smallest limit that could be
accurately, consistently, and safely delivered across
multiple off-axis locations within the larger GTV_2000
tumor using a standard MLC-based delivery. Second, the
diameter provided ample margin to minimize the impact
of dose smearing caused by daily setup variations; thus,
maintaining the desired 100% to 30% dose falloff. Third,
the 1.5 cm spacing between the PTV_6670 and
PTV_Avoid vertices represented the minimum achievable
distance needed to create the desired dose falloff (Fig E1).
Furthermore, the overall Lattice structure was critical in
defining desired fluence paths to reach internal PTV_6670
vertices without increasing the dose to the PTV_Avoid
vertices (Fig E2). The described planning method is not
the exclusive means to create Lattice SBRT plans, but a
consistent procedure that can be applied successfully
across a broad range of tumor volumes, sites, and clinics.
All plans passed QA testing per a SBRT QA protocol
with EPID portal dosimetry at 3%/3 mm and 2%/2 mm,
IC absolute dose measurements at high- and low-dose
points, and Dyna QA to confirm mechanical deliverability
of plans. The increased variability in the low-dose IC
measurements is attributed to the higher inaccuracy of the
inter- and intra-MLC modeling and the associated length
of time that low-dose regions are covered under the MLCs
during the treatment process. Of note, the reported values
are relative to the expected local dose produced in the
treatment planning system, resulting in a deviation of
approximately 5%, which is equivalent to 1 Gy in the
low-dose measurements. This approximate 5% local de-
viation in the low-dose region corresponds to approxi-
mately 1% to 2% of the global prescription, and is within
the 2% tolerance for IC measurements as specified in
AAPM Task Group 218.17 Both the IC- and EPID-based
measurements followed the program standards and QA
recommendations provided in AAPM Task Group 218.
EPID-based measurements are inherently perpendicular to
the delivery direction; thus, the full arc-by-arc fluence
distribution is evaluated against the corresponding distri-
bution produced in the planning system.
This study has limitations inherent to its retrospective
nature. For example, all patients were clinical treated per a
palliative regime. As such, optimal patient positioning
and immobilization for SBRT treatments was not always
present. For example, in 2 lung cases, the patient’s arms
were positioned down and directly in the beam path for all
arcs. To maintain standard lung SBRT positioning, the
arms were subsequently overridden to air. Additionally,
many patients did not have immobilization common for
SBRT treatments, including abdominal compression and
body-length immobilization bags. However, these limi-
tations would impact the delivery of the Lattice plans and
not the planning procedure described in this study.
Standard SBRT positioning, immobilization, and on-
treatment imaging practices should be followed for any
patients treated using the Lattice procedure described in
this study.
We recently completed an evaluation of the safety of
this regimen in a Phase a clinical trial for patients with
large, unresectable tumors (NCT04133415), and are now
evaluating its efficacy for patients with specific histol-
ogies (NCT04553471). Future work will evaluate deliv-
ering Lattice SBRT using intensity modulated proton
therapy and magnetic resonance-guided adaptive radiation
therapy platforms.
Conclusions
Lattice SBRT is an approach to deliver dose-escalated
radiation to large tumors in a way that may surmount the
limitations of conventional fractionation. Our approach
uses VMAT to deliver high-dose islands within a sea of
lower doses. Our approach is clinically and technically
feasible, and being prospectively evaluated in 2 ongoing
trials for patients with large, unresectable tumors.
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